Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs
Only $400 million in 3 newly filed IPOs were raised in Q1 2023 – 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022.
Q2 of 2021 saw the most significant number of IPO filings, resulting in a total amount raised of $12.6 billion. However, certain companies had to withdraw their IPO filings due to extended timelines from the first filing and adverse market conditions.
SPAC – IPOs
In Q1 of 2023, there were merely 2 SPAC IPO filings, raising $100 million. However, the healthcare and life sciences sector experienced no notable growth since Q4 of 2021, which saw 26 SPAC IPOs raising $4.3 billion. The industry’s most significant fund generation was in Q1 of 2021, with 39 SPAC IPO filings and $11.8 billion raised.
IPO Filings – Q1 2023
- CytoMed Therapeutics Limited, a preclinical biopharmaceutical company focused on developing novel cell-based immunotherapies for cancer treatment, priced its IPO of 2,412,369 ordinary shares at $4.00 per share for gross proceeds of $9,649,476. The company granted underwriters an option to purchase 361,855 ordinary shares to cover over-allotments. The shares are expected to trade on Nasdaq as “GDTC” The offering is set to close on April 18, 2023.
- TransCode Therapeutics, Inc. has signed a deal with investor White Lion Capital, LLC, to sell up to $1.08 million of its common stock until May 31, 2023, for working capital and general corporate purposes. TransCode specializes in developing RNA therapeutics for cancer, focusing on glioblastoma and other difficult-to-treat cancers.
DealForma customers: Search for all IPOs
